New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

Jersey City, New Jersey - Organon has recently unveiled an analysis of Phase 3 pooled data for VTAMA (tapinarof) cream, 1%, demonstrating early and consistent improvements in eczema patients across various age groups. This analysis presents promising results for the medication, showcasing its effectiveness in treating eczema. This is a significant development in the field of dermatology, highlighting the potential of VTAMA cream in providing relief to individuals suffering from eczema.